健康父母，为何会生下罕见病宝宝？答案与预防关键都在这里

Core Viewpoint - The breakthrough in gene therapy and the improvement of early screening and prevention systems are providing hope for families affected by rare diseases, which impact a significant global population despite their low individual incidence [1][2]. Group 1: Rare Disease Overview - There are over 10,000 identified rare diseases globally, with approximately 80% being genetically related, affecting around 250 to 300 million people worldwide [2][3]. - Rare diseases can affect any organ or system in the body, with high mortality and disability rates, particularly in children, where over 50% of cases manifest during childhood [2][3]. - Diagnosis of rare diseases is challenging, with many conditions only identifiable through symptom-based diagnosis, leading to a "diagnostic dilemma" for patients [2]. Group 2: Genetic Basis and Inheritance - Rare diseases are primarily caused by genetic mutations, which can be inherited from parents or arise as new mutations during an individual's life [6][9]. - The inheritance patterns include recessive inheritance, X-linked inheritance, and de novo mutations, with specific implications for the likelihood of disease manifestation in offspring [6][9]. Group 3: Screening and Prevention - Early screening is crucial for preventing genetic rare diseases, focusing on three key stages: preconception, prenatal, and neonatal [9][10]. - Preconception screening can identify carrier status for genetic mutations, while prenatal diagnostics can detect inherited conditions early in pregnancy [9][10]. - Neonatal screening is essential for early intervention, with advancements in genetic testing technologies allowing for rapid diagnosis [10]. Group 4: Gene Therapy Developments - Gene therapy offers treatment options for rare diseases, primarily through gene replacement, gene editing, and RNA modification techniques [12][13]. - AAV vector technology has shown significant progress in clinical applications, particularly for spinal muscular atrophy (SMA), where treatment can lead to substantial developmental improvements [12]. - Despite advancements, gene therapy currently addresses less than 10% of rare diseases, with challenges such as delivery mechanisms and the need for early intervention remaining critical [12][13]. Group 5: Policy and Support - The Chinese government is enhancing support for rare disease research and treatment through policy initiatives, improved diagnostic technologies, and healthcare networks [3][13]. - Clinical trial information and funding opportunities for rare disease treatments are becoming more accessible, helping to alleviate the financial burden on affected families [13].